Arran Chemical Company Completes Stage II of its Strategic Plan “ADAPT”
Completion of multi-million Euro expansion of manufacturing capacity and deployment of next generation production technologies
Athlone, Ireland, 09 October 2018 – as reported in October 2017, Irish based Arran Chemical Company, has responded to client demand for the provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its three stage ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment. The investment is focused around increasing capacity, further application of its selectAZyme™ biocatalysis technology and implementation of flow chemistry. Arran is proud to announce the completion of Stage II of the strategy and the positive benefit to its global client base.
Following acquisition by the Almac Group in November 2015, Arran has completed a sustained programme of investment in people and infrastructure to meet growing product diversity and production demands. As reported in 2017, Arran’s manufacturing plant assets have been upgraded bringing total manufacturing capacity to approximately 85 m3 with vessels ranging from kilo laboratory scale to 8 m3. The final phase of investment will involve the introduction of specialist flow manufacturing technologies.
“With the completion of Stage II of our ADAPT strategy, we deliver on our promise to our clients to offer solutions which are economically sound, safe, scalable and high quality through the application of new capacity and enzyme technology.” said Prof. Tom Moody, VP Technology Development and Commercialisation, Arran Chemical Company. “We are determined to remain at the forefront of innovation to ensure our customers receive best-in-class solutions with uninterrupted supply. This will be further augmented with the initiation of Stage III and subsequent build of flow chemistry capabilities.”
Visit Arran Chemical Company at CPhI on stand 1J53.
About Arran Chemical Company
Arran Chemical Company – a member of the Almac Group – is a fine chemical company specialising in the manufacture of products for pharmaceutical and health care, flavour/fragrance, personal care, and other specialised chemical and industrial applications.
We are specialists in chiral chemistry using both chemocatalysis and biocatalysis technologies, but also have practical operating experience over a wide range of modern synthetic reactions. We offer our clients superior chemical solutions with a high rate of success.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5,000 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.